Enhanced HIV Acquisition Risk in the STEP Study Wanes Over Time

May 4, 2012

Following on the heels of the prior post, a new paper published online today in the Journal of Infectious Diseases confirms that uncircumcised MSM with pre-existing antibody responses to Ad5 experienced an enhanced risk of HIV acquisition in the STEP trial. Importantly, however, this study documents that the effect has waned over time.

Richard Jefferys is the coordinator of the Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog at the Treatment Action Group (TAG). The original blog post may be viewed here.

This article was provided by Treatment Action Group. It is a part of the publication Michael Palm HIV Basic Science, Vaccines & Cure Project.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.